RxDoctor Payments Data

Jennifer Graybill, DO

Internal Medicine · St Petersburg, FLNPI 1497016406

Payments from drug & device makers

$522in general payments, 2019–2025

Across 26 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$133
  • GSK$76
  • Boehringer Ingelheim$59
  • Otsuka America Pharmaceutical, Inc.$48
  • Amgen$48
  • Lilly USA, LLC$40
  • plus $118 from 5 others

What the payments were for

  • Food & beverage$522100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$522 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$270,751
Medicare patients
200
Services billed
2,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban425$129,763
Potassium Chloride259$9,799
Breo ElliptaFluticasone/Vilanterol19$8,201
FiaspInsulin Aspart (Niacinamide)24$7,519
XareltoRivaroxaban25$7,396
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$6,552
Atorvastatin Calcium270$4,674
FarxigaDapagliflozin Propanediol16$4,644
Carbamazepine ErCarbamazepine33$4,170
JardianceEmpagliflozin13$4,053
AlrexLoteprednol Etabonate11$3,422
Bumetanide49$2,662
Levothyroxine Sodium164$2,661
Methenamine Hippurate51$2,531
Duloxetine Hcl32$2,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$76$8,20119 claims
Novo NordiskFiasp$21$7,51924 claims
Johnson & JohnsonXarelto$133$7,39625 claims
AstraZenecaFarxiga$21$4,64416 claims
Boehringer IngelheimJardiance$59$4,05313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →